New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - docetaxel 40 mg/ml;   - injection with diluent - 40 mg/ml - active: docetaxel 40 mg/ml   excipient: citric acid nitrogen polysorbate 80 ethanol nitrogen water for injection - head and neck cancer docetaxel, in combination with cisplatin and fluorouracil is indicated in the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - docetaxel 40 mg/ml;   - injection with diluent - 40 mg/ml - active: docetaxel 40 mg/ml   excipient: citric acid nitrogen polysorbate 80 ethanol nitrogen water for injection - head and neck cancer docetaxel, in combination with cisplatin and fluorouracil is indicated in the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - docetaxel 40 mg/ml;   - injection with diluent - 40 mg/ml - active: docetaxel 40 mg/ml   excipient: citric acid nitrogen polysorbate 80 ethanol nitrogen water for injection - head and neck cancer docetaxel, in combination with cisplatin and fluorouracil is indicated in the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - docetaxel 40 mg/ml - concentrate for infusion - 40 mg/ml - active: docetaxel 40 mg/ml excipient: polysorbate 80 ethanol water for injection

United States - English - NLM (National Library of Medicine)

accord healthcare inc. - docetaxel anhydrous (unii: 699121phca) (docetaxel anhydrous - unii:699121phca) - docetaxel anhydrous 40 mg in 1 ml - docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. docetaxel injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced ga

Malta - English - Medicines Authority

strides arcolab international limited unit 4, metro centre, tolpits lane, watford, hertfordshire, wd 189 ss, united kingdom - docetaxel - concentrate and solvent for solution for infusion - docetaxel 40 mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - docetaxel 40 mg/ml - concentrate for infusion - 40 mg/ml - active: docetaxel 40 mg/ml excipient: polysorbate 80 ethanol water for injection - metastatic breast cancer taxotere is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. taxotere in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - docetaxel 10 mg/ml - concentrate for infusion - 20 mg/2ml - active: docetaxel 10 mg/ml excipient: citric acid ethanol nitrogen polysorbate 80 - metastatic breast cancer docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel sandoz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - docetaxel 10 mg/ml - concentrate for infusion - 80 mg/8ml - active: docetaxel 10 mg/ml excipient: citric acid ethanol nitrogen polysorbate 80 - metastatic breast cancer docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel sandoz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - docetaxel - concentrate and solvent for solution for infusion - docetaxel 40 mg/ml - antineoplastic agents